Vasilii V. Ryazhenov

Vasilii V. Ryazhenov

Auto-generated profile, based on publicly available information

Vasilii V. Ryazhenov

Sechenov University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
AAA. V. Alekhin
A. V. Alekhin
TET. N. Erivantseva
T. N. Erivantseva
VRV. V. Ryazhenov
V. V. Ryazhenov
NLN. N. Lyskov
N. N. Lyskov
NAN. A. Alekhina
N. A. Alekhina
MKM. M. Kuznetsova
M. M. Kuznetsova
The aim of the work was to study the legal aspects of the legislative regulation for manufacturing medicines in a pharmacy organization.Materials and methods. Databases of ConsultantPlus, Cyberleninka, Food and Drug Administration (FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), PubMed, e-library, WIPO Lex were used as search sources. The search was based on the following keywords and phrases: intellectual property, pharmacies+invention, patent, drugs, extemporal+production, orphan+diseases, as well as their Russian counterparts. 133 sources of information, including scientific articles and regulations, were found out; 50 have been included in this review. The analysis of information sources published from 2013 to 2023, was determined by the peculiarities of legislation changes in this area.Results. The article provided an overview of modern, including regulatory practice, pharmaceutical manufacturing in the Russian Federation, and also analyzed the benefits of this activity for the medical community, patients and the state. At the same time, the individualization of drug treatment has made it possible to work out systemic solutions for developing drug therapy methods for special groups of patients for whom the economic feasibility of a pharmaceutical registration and launching such drugs onto the market has been brought into challenge. In addition, pharmacy manufacturing is an accessible tool in the study of the drugs prescribed by a doctor not in accordance with the instructions for medical use (off-label) or in the dosage forms/dosages that are not on the market. Extemporaneous manufacturing can be also a part of the process of “repositioning” drugs on the market, subject to compliance with the requirements for pharmacy manufacturing and control of the prescribed drugs safety. The possibility of pharmaceutic drug manufacturing also makes it possible to partially resolve issues related to intellectual property. As a result of the carried out analysis, the following hypothesis was confirmed: the legislative changes have a similar legal assessment both in Russia and abroad and correspond to the legal practice in resolving intellectual property issues in relation to pharmacy organizations.Conclusion. The renewal of a pharmacy production will improve the availability of the drug care to the population, taking into account individual dosages and dosage forms in various therapeutic areas, and can also become a tool for repositioning drugs or clinical testing of new molecules for rare incurable diseases.

7 May 2024 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
OIO. I. Ivakhnenko
O. I. Ivakhnenko
VRV. V. Ryazhenov
V. V. Ryazhenov
EME. A. Maksimkina
E. A. Maksimkina
VFV. S. Fisenko
V. S. Fisenko
ОСО. В. Савоськин
О. В. Савоськин
MKM. M. Kuznetsova
M. M. Kuznetsova
The accessibility and pharmaceutical care coverage are linked to political, economic and managerial decisions. That fact necessitates the evaluation of the state programs results in the field of the drug provision.The aim of the work was to assess the quantitative results of the implementation of the High-Cost Nosologies program in the Russian Federation from 2008 to 2023 to determine further vectors of its improvement.Materials and methods. The regulatory base of the work was made up of the Russian Federation legislation in the field of the drug provision. The open sources were used as the research information base for the data collection and analysis: reports of federal and regional executive authorities, materials of specialized conferences, results of published studies.Results. The drug coverage under the High-Cost Nosologies (VZN) program is provided for 14 nosologies, 11 of which are classified as orphan diseases. Since its implementation, the HCNs program has been expanded twice by including new nosologies in 2019 and 2020. As of 01 October 2023, the number of patients in the Federal Register of VZN was 263 721 people, which was 13.58 times greater compared to 2008. The drug provision is carried out according to the list of 47 INNs. The amount of funding for the program increased from RUB 32 bn in 2008 to RUB 87.96 bn in 2023. The most resource-intensive nosologies include hemophilia, multiple sclerosis and oncohematology.Conclusion. The main quantitative characteristics of the implementation of the HCNs program and the identified vectors for its further improvement have been analyzed in this study. The results obtained can be used to conduct analytical studies, including the ones within nosologies and nosological groups included in the program, in order to optimize a pharmaceutical care. The focus of improving the implementation of the VZN program is related to the improvement of the legal framework, a patient treatment paradigm and approaches to its financing.

2 May 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EZElena Zakharochkina
Elena Zakharochkina
VRVasily Ryazhenov
Vasily Ryazhenov
ESElena Smolyarchuk
Elena Smolyarchuk
DKDmitry Kudlay
Dmitry Kudlay
NBNаna Bekhorashvili
Nаna Bekhorashvili
SSSusanna Sergeevna Sologova
Susanna Sergeevna Sologova
The off-label use of drugs is a common practice worldwide. The legal basis for off-label medical use varies from country to country. Regulatory control of the pharmaceutical market in the off-label preventive and therapeutic practice at the international and national levels has become a breakthrough with the emergence of the coronavirus pandemic. The prospects for off-label use in the context of innovations in the legislation of public health in the Russian Federation are crucial. Professionally significant aspects of the use of medicinal products outside the Summary of Product Characteristics and the off-label use have been introduced by supranational regulatory authorities for the common market of medicinal products of the Eurasian Economic Union. Special attention should be paid to the regulatory control of the use of extemporaneous medicines as part of improving the government regulation of drug compounding in pharmacies. The active development of pharmacy activities in drug compounding within the framework of improving regulatory practice determines the relevance of actual off-label prescriptions and the use of extemporaneous formulations. Aim – to perform a systematic analysis of national, transnational legislative and regulatory documents regulating off-label use of medicinal products, determine the main conceptual components of the current regulatory pool and directions for future development in this area. Systematic analysis of the national legislative and regulatory pool of documents and the regulatory framework of the common market of medicinal products of the Eurasian Economic Union on the regulation of various aspects of the off-label use of medicinal products. Study of the components and identification of the main trends in the regulatory practice of prescriptions outside the Summary of Product Characteristics and the off-label use. An analytical search was carried out in the reference legal systems "ConsultantPlus" and "Garant" on the official websites of the Ministry of Health of Russia, the Eurasian Economic Union, the RusMed information resource of the National Library resource of Russia in medicine and pharmacy "Central Scientific Medical Library" was used. A logical generalization of the results on the current state of the legal framework and the development of conceptual proposals on the key directions of the prospective development of regulation, control, and supervisory activities of the pharmaceutical off-label use of medicinal products was made.

30 April 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
VRVasilii V. Ryazhenov
Vasilii V. Ryazhenov
SOSergey V. Orlov
Sergey V. Orlov
OIOksana I. Ivakhnenko
Oksana I. Ivakhnenko
РВРяженов Василий Вячеславович
Ряженов Василий Вячеславович
Aim. Impact evaluation of effective methods for advanced small cell lung cancer treatment using the drug durvalumab on the achievement of the Russian Federation national and regional programs Healthcare Development target indicator reduction of mortality from neoplasms. Materials and methods. The methodology of this study is based on general scientific research methods: general logical (analysis, synthesis, induction), theoretical (generalization), empirical (description, calculation, measurement, comparison). The regulatory framework of the research work was made up by the legislation of the Russian Federation, documents regulating the procedure for providing medical care to patients with malignant neoplasms, technical regulation norms enshrined in the documents of the national standardization system that regulate the procedure for health technologies assessment. As an empirical base, the available official data on the epidemiology of lung cancer, Russian and foreign scientific publications, Russian clinical guidelines for the diagnosis and treatment of malignant neoplasms of lungs were analyzed. To conduct health technologies assessment, a mathematical model was developed based on Microsoft Excel 2019 software. The mathematical apparatus used to create a predictive model adapted to predict the results of healthcare cancer programs at the federal and regional levels. Results. The use of durvalumab for the treatment of advanced small cell lung cancer will provide an increase in the achievement of the target indicator reduction of mortality from neoplasms of the national program Healthcare Development in 2022 by 21.3% (499 additionally prevented deaths), in 2023 by 7.0% (366 additionally averted deaths), in 2024 by 6.0% (441 additionally averted deaths). Obtained results show that the use of durvalumab in combination with standard chemotherapy in patients with advanced small cell lung cancer can have a significant impact on the achievement of targets set in healthcare cancer programs. Conclusion. The durvalumab usage in real practice in combination with standard chemotherapy (etoposide + platinum drug), in comparison with the use of only standard chemotherapy (etoposide + platinum drug), will reduce cancer mortality and will contribute to achieving the targets of the Russian Federation national and regional programs Healthcare Development reduction of mortality from neoplasms.

3 May 2024 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
ОIО. I. Ivakhnenko
О. I. Ivakhnenko
VRV. V. Ryazhenov
V. V. Ryazhenov
NFN. A. Falaleeva
N. A. Falaleeva
Objective: to assess clinical and economic implications of adding daratumumab (Dara) to the “lenalidomide + dexamethasone” (Rd) treatment program in early lines of therapy for patients with multiple myeloma (MM) ineligible for high-dose chemotherapy (HDCT) with subsequent autologous hematopoietic stem cell transplantation (autoHPSCT).Material and methods. Partitioned survival model was developed to compare overall survival in the treatment programs of MM patients in the 1st to 3rd lines of therapy. The following treatment options were included in the analysis: 1st line – Dara+Rd; 2nd line – “carfilzomib + lenalidomide” (K+Rd) or “ixazomib + lenalidomide” (Ixa+Rd) triplets; 3rd line – pomalidomide (Pom+dex) and Rd+(Dara+Rd)+(Pom+dex) versus Rd+(K/Ixa+Rd)+(Pom+dex/Dara). Probabilities of transition between health states (progression-free, progressed disease, and death) were based on published clinical data. Lifetime direct healthcare costs and incremental cost-effectiveness ratios (ICERs) per 1 life year gained were calculated from a Russian health care perspective. The indicator of the difference in costs between current and expected practice was used in budget impact analysis.Results. Dara+Rd combination increased life expectancy by 1.04 years (+16.05%) and 0.95 years (+14.57%) per patient, and in the target population (n=955) by 995.48 and 903.40 years for (Dara+Rd)+(K+Rd)+(Pom+dex) and (Dara+Rd)+(Ixa+Rd)+(Pom+dex) treatment programs, respectively, compared to Rd use in the 1st line. The ICER per 1 life year gained for Dara+Rd in 1st line therapy was 8.95 mln rubles for (Dara+Rd)+(K+Rd)+(Pom+dex) and 8.41 mln rubles for (Dara+Rd)+(Ixa+Rd)+(Pom+dex). It's lower than the median ICER of 13.64 million per 1 life year gained for antitumor drugs used to treat cancer of lymphatic and hematopoietic tissues (reference ICER). Dara+Rd triplet is used in 2nd line therapy after Rd, the number of life years gained in the target population due to greater efficacy is higher by 291.50 years compared with K+Rd and by 203.93 years compared with Ixa+Rd. The ICER per 1 life year gained for Dara+Rd is also lower than the ICER reference value: 9.25 mln rubles versus 13.64 mln rubles. The budget impact analysis showed that using Dara in early stages of MM therapy does not increase drug provision costs in the target population.Conclusion. The obtained results allowed to conclude that it is economically feasible to add Dara to the 1st and 2nd lines of therapy in lenalidomide treatment programs for MM patients who are not candidates for HDCT with autoHPSCT.

23 July 2025 in Pharmacy & Pharmacology
Verified
Journal Article
Open access
PDF file
RGR. Yu. Garankina
R. Yu. Garankina
VRV. V. Ryazhenov
V. V. Ryazhenov
EME. A. Maksimkina
E. A. Maksimkina
VFV. S. Fisenko
V. S. Fisenko
AAA. V. Alekhin
A. V. Alekhin
EZE. R. Zakharochkina
E. R. Zakharochkina
To date, pharmaceutical activities in the manufacture of medicines in a pharmacy, intra-pharmacy packaging of registered medicines in Russia and the countries of the Eurasian Economic Union (EAEU), is one of the priorities of regulatory authorities in order to improve drug supply.The aim. To study the current state of legal regulation of the circulation of medicines “in bulk” and the possibility of their packaging in a pharmacy.Materials and methods. To solve the tasks set, the methodology of system analysis in the field of drug provision, content analysis of documents regulating the sphere of circulation of drugs was used. The regulatory framework of the study was the legislative and by-laws regulating the sphere of circulation of medicines of the Russian Federation and the common market of the EAEU. The search for regulatory legal acts was carried out in the Directory of the legal system “ConsultantPlus”. In the course of the research, a set of scientific methods was used such a systematic, logical, structural and comparative.Results. The article consider the issues of legal regulation of the circulation of medicines “in bulk” in the pharmaceutical market. The current state of the legislative and regulatory framework has been studied and the problems of legal regulation of packaging of medicicnes “in bulk” in pharmacies have been identified. The article also focuses on the general problem of compliance with modern packaging requirements for medicines compounded in pharmacy. The possibility of introducing a new concept of “Pharmacy packaging” into Federal Law No. 61-FZ dated April 12, 2010 “On the circulation of medicines” is considered. The approaches developed in world practice to the regulation of issues related to the packaging of drugs “in bulk” in pharmacy are considered. Based on the results of the study, the possibilities have been identified and ways to improve the mechanisms of state regulation have been proposed.Conclusion. Packaging of medicines “in bulk” will increase the effectiveness of individual drug therapy, optimize and reduce the cost of circulation of budget funds, pharmacies and citizens.